Lenvatinib

#	Item
1	TM FDA Approves Eisai’s LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer • • Add to Reading List Source URL: www.thyroid.org Language: English - Date: 2015-02-24 17:47:41
2	NoFebruary 16, 2015 Eisai Co., Ltd. U.S. FDA APPROVES ANTICANCER AGENT LENVIMATM Add to Reading List Source URL: www.eisai.com Language: English - Date: 2015-02-15 19:14:10 Anatomy Papillary thyroid cancer Lenvatinib Protein kinase inhibitor Thyroid Hepatocellular carcinoma Non-small-cell lung carcinoma Iodine-131 Renal cell carcinoma Medicine Thyroid cancer Endocrinology
3	No[removed]October 15, 2014 Eisai Co., Ltd. U.S. FDA GRANTS PRIORITY REVIEW STATUS TO Add to Reading List Source URL: sfj-pharma.com Language: English - Date: 2014-10-31 18:17:26 Biology Papillary thyroid cancer Thyroid Receptor tyrosine kinase Iodine-131 Lenvatinib Eisai Medullary thyroid cancer Follicular thyroid cancer Thyroid cancer Anatomy Medicine